Blurbs

Analysts Are Bullish on These Healthcare Stocks: Idexx Laboratories (IDXX), Sarepta Therapeutics (SRPT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Idexx Laboratories (IDXXResearch Report) and Sarepta Therapeutics (SRPTResearch Report) with bullish sentiments.

Idexx Laboratories (IDXX)

Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Idexx Laboratories on June 24 and set a price target of $500.00. The company’s shares closed last Friday at $361.48, close to its 52-week low of $318.50.

According to TipRanks.com, Block is a 5-star analyst with an average return of 13.8% and a 58.0% success rate. Block covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Envista Holdings, and DENTSPLY SIRONA.

Idexx Laboratories has an analyst consensus of Moderate Buy, with a price target consensus of $583.83.

See the top stocks recommended by analysts >>

Sarepta Therapeutics (SRPT)

In a report issued on June 23, Brian Abrahams from RBC Capital maintained a Buy rating on Sarepta Therapeutics, with a price target of $155.00. The company’s shares closed last Friday at $75.22.

According to TipRanks.com, Abrahams is a 1-star analyst with an average return of -1.6% and a 45.3% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Vertex Pharmaceuticals.

Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $124.14, a 76.1% upside from current levels. In a report issued on June 24, Mizuho Securities also maintained a Buy rating on the stock with a $160.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on IDXX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos